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Background
Chronic myelogenous leukemia (CML) is a leukemic stem
cell (LSC)-driven myeloproliferative disorder and is asso-
ciated with a characteristic chromosomal translocation
which generates a constitutively active tyrosine kinase, the
BCR-ABL oncoprotein. The standard treatment therapy
for CML patients is the BCR-ABL tyrosine kinase inhibitor
(TKI) imatinib. It is a life-long treatment due to the fact
that LSCs are resistant to TKIs. Since its introduction,
imatinib has improved the 5-year survival rate up to 90%.
An emerging problem is resistance to imatinib, which is
mainly caused by mutations inside the BCR-ABL kinase
domain, and its increasing incidence during disease pro-
gression. It has been reported that BCR-ABL drives its
own mutation via upregulation of reactive oxygen species
(ROS) causing oxidative DNA damage. Among the several
dozens of intensively characterized mediators of BCR-ABL
action, the transcription factor STAT5 is among the few
ones that is critical for leukemia initiation and mainte-
nance and it has been shown that STAT5 becomes upre-
gulated during disease progression.
Methods and results
qPCR analysis of primary CML patient samples reveal a
positive correlation of STAT5 mRNA levels and BCR-
ABL mutations. Using BCR-ABL transformed murine
cell lines retrovirally overexpressing STAT5A or
STAT5B, we can show that STAT5 triggers ROS pro-
duction leading to an increase in DNA double-strand
breaks.
Conclusions
We hypothesize that STAT5 is an important mediator
of imatinib resistance in CML due to its ability to drive
ROS production consequently leading to BCR-ABL
mutations.
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